AcureOmics AB

AcureOmics AB, a company based in Umeå, Sweden, is a leader in metabolomics and metabolic profiling on autoimmune diseases, including rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE) and diabetes (T1D,T2D,MODY). Together with clinicians, biotech companies, patient organizations and universities we develop therapeutic, diagnostic and prognostic biomarkers for more individual-based, personalized healthcare. AcureOmics is also part of BOLD (Biology of Liver and Pancreatic Development and Disease), a Marie Curie Initial Training Network (ITN) within EU's FP7 program 2009-2013.
Cutting-edge metabolomics services we offer:

Metabolomics for the diagnosis of disease, and severity of disease

Provide validated insights into the complex biochemical processes in disease, diagnosis, treatment and prognosis

Evaluate existing drugs on the market for new indications

Metabolomics for developing and evaluating new chemical entities (CE)

Contact details
Email: ceo at acureomics.com
Website: www.acureomics.com